LIFE, US0021202025

aTyr Pharma stock faces October 16 reverse split vote

Published on 10/07/2026 at 01:25 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

aTyr Pharma stock faces an October 16 vote on a 1-for-10 to 1-for-50 reverse split. ATYR was last at USD 0.28 on October 6, 2026.

LIFE, US0021202025, Illustration mit AI erstellt.

aTyr Pharma stock (ISIN US0021202025) was last at USD 0.28 on Nasdaq on October 6, 2026 at 4:00 p.m. ET, down 2.28 percent from the prior close. The key date is October 16, 2026, when shareholders vote on a proposed reverse stock split.

Reverse split vote is October 16

According to StockTitan in the proxy filing dated September 11, 2026, aTyr is asking shareholders to authorize a reverse split at a ratio between 1-for-10 and 1-for-50. The board would decide whether to implement the split and which ratio to use after the meeting.

The filing lists 98,087,425 common shares outstanding as of September 4, 2026. A reverse split would reduce the share count while leaving each holder's ownership percentage broadly unchanged, subject to the treatment of fractional shares.

Nasdaq deadline shapes the proposal

The proxy states that Nasdaq requires a minimum bid price of USD 1.00 per share. aTyr received an additional compliance period ending November 30, 2026, giving the company a defined deadline to regain compliance.

That requirement is material against the market data: ATYR's October 6 price of USD 0.28 was 75.00 percent below the 52-week high of USD 1.12 and 3.70 percent above the 52-week low of USD 0.27. The proposed split is therefore a listing-compliance measure as well as a capital-markets decision.

Efzofitimod remains the operating catalyst

In its September 24, 2026 release, aTyr Pharma said it had aligned with the FDA on the protocol for a global Phase 3 efzofitimod study in pulmonary sarcoidosis. The planned trial will run for 54 weeks, use a 5.0 mg/kg dose every three weeks and measure forced vital capacity at week 48 as its primary endpoint.

The company also said the study will require additional capital through potential equity or debt offerings, grants, collaborations, partnerships or licensing arrangements. That funding requirement is the central counter-factor to the regulatory progress.

ATYR remains a microcap biotech

aTyr had a market capitalization of USD 27.8 million and traded 1,020,070 shares on October 6, 2026. The session range was USD 0.28 to USD 0.29, putting the stock near the bottom of its one-year range while the October 16 vote approaches.

aTyr Pharma stock was last at USD 0.28 on Nasdaq on October 6, 2026 at 4:00 p.m. ET. The proposed split, the November 30 compliance deadline and the planned Phase 3 program now define the company's immediate market narrative.